End of GAPVAC patient recruitment (July 2016)

With 16 patients enrolled in the GAPVAC trial, patient recruitment was closed in July 2016. Patients have been recruited by the six clinical sites Tübingen, Heidelberg, Genève, Barcelona, Leiden and Copenhagen. The individual targets have already been selected for all enrolled patients and the biomarker-guided APVAC selection process worked very well. Out of the 16 enrolled patients, 13 received APVAC1 and/or APVAC2 vaccinations by now. Patient treatment will presumably be completed in Q2 2017.